US · MAZE
Maze Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- mazetx.com
Price · as of 2024-12-31
$27.17
Market cap 2.19B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $7.24 | -73.35% |
| Graham-Dodd Method(GD) | $10.46 | -61.51% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | $12.00 | $3.98 | $10.46 |
AI valuation
Our deep-learning model estimates Maze Therapeutics, Inc.'s (MAZE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $27.17
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$7.24
-73.35% upside
Graham-Dodd
$10.46
-61.51% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MAZE | Maze Therapeutics, Inc. | $27.17 | 2.19B | — | -73% | -62% | — | 10.06 | 2.67 | 3.14 | 5.84 | — | 2.67 | 100.00% | 34.38% | 31.18% | 50.47% | 196.80% | 33.48% | 0.14 | — | 9.76 | 9.52 | -2.80 | -10339.00% | — | -18572.00% | 14.23% | 3.67 | 261.38% | 0.00% | 0.00% | 36.28% | 6.17 | 4.75 | 2.12 | 7.53 |
| ARDX | Ardelyx, Inc. | $6.55 | 1.59B | +365% | +11,362% | — | — | -25.32 | 9.34 | 3.83 | -51.64 | -47.82 | 9.34 | 90.29% | -10.06% | -15.12% | -36.21% | -43.02% | -13.14% | 1.27 | -1.44 | 4.31 | 3.80 | -4.92 | 5294.00% | 2209.00% | -403.00% | -2.82% | -0.48 | -46.17% | 0.00% | 0.00% | 0.00% | -36.76 | -34.26 | 3.70 | 1.40 |
| BCRX | BioCryst Pharmaceuticals,… | $8.75 | 1.84B | +993% | +143,402% | -35% | +1,311% | 6.86 | -15.20 | 2.07 | 4.45 | — | -15.20 | 97.82% | 38.98% | 30.16% | -88.68% | -199.20% | 52.53% | -0.10 | 4.32 | 2.06 | 1.40 | -0.22 | -38140.00% | 9410.00% | -75364.00% | 19.18% | 1.77 | -205.64% | 0.00% | 0.00% | 44.97% | 4.54 | 4.46 | 1.77 | 1.99 |
| IMNM | Immunome, Inc. | $21.86 | 2B | +132% | -83% | — | +492% | -1.87 | 3.02 | 60.58 | -2.21 | — | 3.02 | 100.00% | -3382.37% | -3240.38% | -194.63% | 1276.40% | -150.71% | 0.03 | — | 4.08 | 4.00 | 0.92 | -706.00% | -3550.00% | 185621.00% | -30.00% | -2.04 | 685.79% | 0.00% | 0.00% | 7.58% | -1.10 | -2.04 | 37.08 | -0.77 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| PHVS | Pharvaris N.V. | $28.39 | 1.84B | — | — | — | — | -5.23 | 2.59 | — | -2.84 | — | 2.59 | 0.00% | — | — | -40.62% | 1529.52% | -38.37% | 0.00 | — | 12.60 | 12.35 | 1.92 | -570.00% | — | 2956.00% | -17.42% | -5.23 | 1266.85% | 0.00% | 0.00% | 0.00% | -2.83 | -3.42 | — | 15.12 |
| SION | Sionna Therapeutics, Inc. | $36.54 | 1.63B | — | — | — | — | -11.64 | -4.39 | — | -8.30 | -37.90 | -4.39 | 0.00% | — | — | 44.29% | 31.75% | -51.90% | -0.06 | — | 14.49 | 14.16 | 0.40 | 3071.00% | — | 1785.00% | -7.36% | -5.07 | 23.77% | 0.00% | 0.00% | 0.00% | -8.22 | -10.98 | — | -0.48 |
| SYRE | Spyre Therapeutics, Inc. | $43.01 | 2.6B | — | — | — | — | -94.74 | 20.56 | — | -66.55 | — | 20.56 | 0.00% | — | — | -25.17% | 331.08% | -22.39% | 0.00 | — | 13.25 | 12.89 | 0.41 | -3774.00% | — | 752.00% | -1.15% | -2.88 | 267.42% | 0.00% | 0.00% | 0.00% | -66.55 | -82.40 | — | 139.24 |
| TRVI | Trevi Therapeutics, Inc. | $11.92 | 1.53B | — | — | — | — | -9.07 | 4.36 | — | -6.86 | -14.61 | 4.36 | 0.00% | — | — | -52.59% | 1707.29% | -47.84% | 0.01 | -12881.00 | 10.41 | 10.29 | 0.69 | 6207.00% | — | 2023.00% | -8.81% | -3.64 | 1269.60% | 0.00% | 0.00% | 0.46% | -6.36 | -8.56 | — | 19.07 |
| WVE | Wave Life Sciences Ltd. | $13.93 | 2.59B | +134% | -54% | — | +334% | -11.43 | 4.51 | 54.67 | -8.57 | -15.69 | 4.51 | 0.00% | -504.09% | -478.33% | -56.16% | 323.63% | -108.74% | 0.03 | — | 6.47 | 6.35 | 2.86 | 7286.00% | -6055.00% | 2338.00% | -8.03% | -1.97 | 281.72% | 0.00% | 0.00% | 13.17% | -8.13 | -9.34 | 40.99 | 1.20 |
| ZYME | Zymeworks Inc. | $23.29 | 1.74B | +9% | -79% | — | — | -7.42 | 2.69 | 11.93 | -6.47 | — | 2.83 | 100.00% | -179.69% | -160.80% | -30.54% | -110.26% | -23.51% | 0.05 | — | 3.40 | 3.19 | 0.44 | -581.00% | 38.00% | -757.00% | -12.43% | -1.25 | -90.96% | 0.00% | 0.00% | 3.30% | -5.13 | -6.21 | 9.21 | 1.62 |
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
- CEO
- Jason V. Coloma
- Employees
- 125
- Beta
- 4.52
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($7.24 ÷ $27.17) − 1 = -73.35% (DCF, example).